License and Collaboration Arrangements (Additional Information) (Details) - USD ($) $ in Thousands		3 Months Ended
	Apr. 24, 2024	Mar. 31, 2024	Mar. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		$ 77,499	$ 76,372
Zai Lab | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost incurred for supply chain activities	$ 8,100
Zai Lab | Research and Development Support
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable		91,000
PAION AG
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable		109,500
PAION AG | Cost Reimbursement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		0	0
Everest Medicines Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone payments receivable		$ 20,000
License revenue recognized			8,000
Royalties payable period after first commercial sale of product		10 years
Everest Medicines Limited | Commercial Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of reimbursed for direct and certain indirect manufacturing costs		110.00%
George Washington University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales		6.00%
Percentage of royalty on payments received from sublicensees		15.00%
Harvard University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales		5.00%
Percentage of royalty on payments received from sublicensees		20.00%
Cost of license revenue			$ 1,600
Clinical development and regulatory milestones amount payable		$ 15,100
Percentage of minimum royalty rate		4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds		7.50%
Paratek Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales		2.25%
Claim expiration		2023-10
Astrazeneca
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time Milestone Payment on Net Sales		$ 5,000
Term of Milestone Payment for Net Sales		3 months
One-time Milestone Payment on Commercial Sales		$ 10,000
Term of Milestone Payment for Commercial Sale		2 years